EUVIMEDOpdag EUVIMED
BeobachtungsstudieOpen access · CC BY 4.0

Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer

Bandana Kumari, Rijhul Lahariya

GMS German Medical Science · 2025-11-20 · 23 (Doc16) · Doc16

DOI: 10.3205/000352 ↗

At a glance

Beobachtungsstudie in GMS German Medical Science, published on 2025-11-20. Written by Bandana Kumari and 1 co-authors. Institution: Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India. Major MEDLINE topics: Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Receptors, Progesterone, Biomarkers, Tumor. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objectives

Invasive ductal carcinoma (IDC), the most prevalent subtype of breast cancer, is characterized by significant genomic heterogeneity. Tumor mutation burden (TMB) has emerged as a predictive biomarker for immunotherapy response, yet its estimation via whole-exome sequencing remains complex and costly. This study aimed to evaluate whether total somatic mutation count can serve as a practical surrogate for TMB and assess its association with progesterone receptor (PR) status in PIK3CA-mutated IDC patients.

Methods

This retrospective observational study utilized publicly available data from a previously published breast cancer sequencing study. A total of 164 female IDC patients with confirmed PIK3CA mutations and documented PR status were included. Relevant genomic and demographic parameters – TMB, mutation count, and age – were extracted and analyzed. Statistical analyses included correlation, intergroup comparisons by PR status, and binary logistic regression. Predictive performance was assessed using area under the receiver operating characteristic (AUROC) curves.

Results

Patients with PR-negative status exhibited significantly higher TMB and mutation count than PR-positive patients (p-value

Subjects

MeSH terms (MEDLINE)

Class I Phosphatidylinositol 3-KinasesBreast NeoplasmsReceptors, ProgesteroneBiomarkers, TumorCarcinoma, Ductal, BreastHumansFemaleRetrospective StudiesMiddle AgedMutationAdultAged

Author keywords

PIK3CA mutationbreast invasive ductal carcinomaprogesterone receptorsomatic mutationtumor mutation burden

Substances

Class I Phosphatidylinositol 3-KinasesPIK3CA protein, humanReceptors, ProgesteroneBiomarkers, Tumor

Authors and institutions

  • Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India.
  • All India Institute of Medical Sciences, Patna, Bihar, India.

Cite

APA

Kumari, B., & Lahariya, R. (2025). Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer. GMS German Medical Science, 23(Doc16), Doc16. https://doi.org/10.3205/000352

Vancouver

Kumari B, Lahariya R. Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer. GMS German Medical Science. 2025;23(Doc16):Doc16. doi:10.3205/000352

BibTeX
@article{Kumari2025,
  author = {Kumari, Bandana and Lahariya, Rijhul},
  title = {Somatic mutation counts as a surrogate marker for tumor mutation burden to predict progesterone receptor-positive (PR+) status in PIK3CA-mutated breast cancer},
  journal = {GMS German Medical Science},
  year = {2025},
  volume = {23},
  number = {Doc16},
  pages = {Doc16},
  doi = {10.3205/000352}
}
Start for free →